{"id":485595,"date":"2021-05-03T07:08:55","date_gmt":"2021-05-03T11:08:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/"},"modified":"2021-05-03T07:08:55","modified_gmt":"2021-05-03T11:08:55","slug":"aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/","title":{"rendered":"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">TORONTO, May  03, 2021  (GLOBE NEWSWIRE) &#8212; Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (\u201cAleafia Health\u201d or the \u201cCompany\u201d), a global leader in cannabis wellness products and services, has secured a Health Canada Research Licence for its cannabis product manufacturing and innovation centre in Paris, Ont. The licence allows the Company to conduct human sensory analysis and palatability trials, evaluating the taste, touch, smell and sight of its growing portfolio of differentiated medical and consumer cannabis products.<\/p>\n<p>\u201cAs we continue to bring highly innovative\u00a0formats to market, our development team will now employ an important best practice of product evaluation used in the food and beverage industries,\u201d said Aleafia Health CEO Geoffrey Benic. \u201cThrough a first to market product strategy, we\u2019ve developed a track record for product innovation that will only be strengthened by this regulatory breakthrough.\u201d<\/p>\n<p>Aleafia Health is currently developing a number of new product formats and line extensions to complement its existing cannabis portfolio of dried flower, edibles, sublingual strips, soft gels, extracts, and vape cartridges. The Company intends to conduct sensory assessment studies consistently during product development, allowing human panels to evaluate objective product characteristics, and evaluate preference between comparable products.<\/p>\n<p>\n        <strong>For Investor &amp; Media Relations:<\/strong>\n      <\/p>\n<p>Nicholas Bergamini, VP Investor Relations<br \/>1-833-879-2533<br \/>IR@AleafiaHealth.com<br \/>LEARN MORE: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gBodXKoXBMct4VZyvpijlDasFHlwcoo_SiUyEFkHqIJ66TBBJRK3EfgI0KEDu5y43k5hIvJFwS7bLNUQXYRGZWGEsujwgu44oQunc23WBSw=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.AleafiaHealth.com<\/u><\/a><\/p>\n<p>\n        <strong>About Aleafia Health<\/strong>:<\/p>\n<p>Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and with sales and operations in Australia and Germany. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.<\/p>\n<p>Aleafia Health owns four significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules, edibles, sublingual strips, and vapes. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.<\/p>\n<p>\n        <strong>Forward Looking Information<\/strong>\n      <\/p>\n<p>This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as \u201cplans\u201d, \u201cexpects\u201d, \u201cestimates\u201d, \u201cintends\u201d, \u201canticipates\u201d, or \u201cbelieves\u201d or variations of such words and phrases or state that certain actions, events or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d or \u201cwill\u201d be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company\u2019s annual information form filed with Canadian securities regulators available on the Company\u2019s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0ba4d8bc-5c78-4cb1-b21b-c62738db9c57\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO, May 03, 2021 (GLOBE NEWSWIRE) &#8212; Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (\u201cAleafia Health\u201d or the \u201cCompany\u201d), a global leader in cannabis wellness products and services, has secured a Health Canada Research Licence for its cannabis product manufacturing and innovation centre in Paris, Ont. The licence allows the Company to conduct human sensory analysis and palatability trials, evaluating the taste, touch, smell and sight of its growing portfolio of differentiated medical and consumer cannabis products. \u201cAs we continue to bring highly innovative\u00a0formats to market, our development team will now employ an important best practice of product evaluation used in the food and beverage industries,\u201d said Aleafia Health CEO Geoffrey Benic. \u201cThrough a first to market product strategy, we\u2019ve &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-485595","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO, May 03, 2021 (GLOBE NEWSWIRE) &#8212; Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (\u201cAleafia Health\u201d or the \u201cCompany\u201d), a global leader in cannabis wellness products and services, has secured a Health Canada Research Licence for its cannabis product manufacturing and innovation centre in Paris, Ont. The licence allows the Company to conduct human sensory analysis and palatability trials, evaluating the taste, touch, smell and sight of its growing portfolio of differentiated medical and consumer cannabis products. \u201cAs we continue to bring highly innovative\u00a0formats to market, our development team will now employ an important best practice of product evaluation used in the food and beverage industries,\u201d said Aleafia Health CEO Geoffrey Benic. \u201cThrough a first to market product strategy, we\u2019ve &hellip; Continue reading &quot;Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-03T11:08:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products\",\"datePublished\":\"2021-05-03T11:08:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/\"},\"wordCount\":617,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/\",\"name\":\"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=\",\"datePublished\":\"2021-05-03T11:08:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/","og_locale":"en_US","og_type":"article","og_title":"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products - Market Newsdesk","og_description":"TORONTO, May 03, 2021 (GLOBE NEWSWIRE) &#8212; Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (\u201cAleafia Health\u201d or the \u201cCompany\u201d), a global leader in cannabis wellness products and services, has secured a Health Canada Research Licence for its cannabis product manufacturing and innovation centre in Paris, Ont. The licence allows the Company to conduct human sensory analysis and palatability trials, evaluating the taste, touch, smell and sight of its growing portfolio of differentiated medical and consumer cannabis products. \u201cAs we continue to bring highly innovative\u00a0formats to market, our development team will now employ an important best practice of product evaluation used in the food and beverage industries,\u201d said Aleafia Health CEO Geoffrey Benic. \u201cThrough a first to market product strategy, we\u2019ve &hellip; Continue reading \"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-03T11:08:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products","datePublished":"2021-05-03T11:08:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/"},"wordCount":617,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/","name":"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=","datePublished":"2021-05-03T11:08:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIyODA1NSM0MTYwMzAyIzIxMjMzNzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aleafia-health-secures-health-canada-research-licence-for-human-sensory-analysis-trials-of-cannabis-products\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aleafia Health Secures Health Canada Research Licence for Human Sensory Analysis Trials of Cannabis Products"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=485595"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/485595\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=485595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=485595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=485595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}